Curis to Present at 21st Annual Needham Virtual Healthcare Conference
Curis, Inc. (NASDAQ: CRIS), a biotechnology firm focusing on cancer therapeutics, will have its CEO James Dentzer present at the 21st Annual Needham Virtual Healthcare Conference. This presentation will be available for on-demand viewing starting April 12, 2022, at 8:45 a.m. ET. Investors can access a live webcast on the company's website, with a replay available for 90 days post-event. Curis is known for its collaborations in immuno-oncology and its ongoing clinical trials for therapies like emavusertib, aimed at non-Hodgkin's lymphoma and acute myeloid leukemia.
- None.
- None.
LEXINGTON, Mass., April 5, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company overview at the 21st Annual Needham Virtual Healthcare Conference. The presentation will be available for on-demand viewing starting on Tuesday, April 12, 2022 at 8:45 a.m. ET.
A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website at www.curis.com. A replay of the webcast will be available on the Curis website for 90 days following the event.
About Curis, Inc.
Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, emavusertib (CA-4948). Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma trial, in patients with non-Hodgkin's lymphoma both as a monotherapy and in combination with BTK inhibitor ibrutinib. Curis is also evaluating emavusertib in the Phase 1/2 TakeAim Leukemia trial in patients with acute myeloid leukemia and myelodysplastic syndromes, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1 trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-present-at-21st-annual-needham-virtual-healthcare-conference-301517055.html
SOURCE Curis, Inc.
FAQ
What is Curis's stock symbol and event on April 12, 2022?
When can I view the Curis presentation from the Needham Conference?
Where can I find the webcast of Curis's presentation?
What ongoing trials is Curis involved in?
What is the significance of emavusertib in Curis's research?
